Shyamal H Mehta1, Rajesh Pahwa2, Caroline M Tanner3, Robert A Hauser4, Reed Johnson5. 1. Department of Neurology, Mayo Clinic-Scottsdale, 13400 East Shea Blvd, Scottsdale, AZ, 85254, USA. mehta.shyamal@mayo.edu. 2. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Department of Neurology, University of California, San Francisco, CA, USA. 4. USF Parkinson's Disease and Movement Disorders Center Parkinson Foundation Center of Excellence, University of South Florida, Tampa, FL, USA. 5. Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.
Abstract
INTRODUCTION:Gocovri (amantadine) extended release capsules are approved for treatment of dyskinesia and as a levodopa adjunct for OFF episodes in patients with Parkinson's disease (PD). We report treatment-related effects on non-motor symptoms (NMS) assessed as secondary outcomes in two trials using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I. METHODS: EASE LID and EASE LID 3 enrolled levodopa-treated patients with PD and ≥ 1 h/day ON time with troublesome dyskinesia. Patients were randomized to Gocovri (274 mg) or placebo taken daily at bedtime. Treatment differences from baseline to week 12 in MDS-UPDRS Part I were evaluated for the pooled population (N = 196) from both trials. Correlation analyses of NMS (MDS-UPDRS Part I) with dyskinesia using Unified Dyskinesia Rating Scale (UDysRS) scores were performed. RESULTS: For changes in the MDS-UPDRS Part I items, the treatment difference favored Gocovri in daytime sleepiness (P = 0.006) and depression (P = 0.049) scores, but favored placebo in cognitive impairment (P = 0.038), and hallucinations and psychosis (P < 0.001) scores. The treatment difference for the changes in total Part I score was -0.8, favoring Gocovri (P = 0.22). At baseline, MDS-UPDRS Part I modestly correlated with UDysRS score (r +0.25, P < 0.001), and improvement in NMS correlated with improvement in dyskinesia at week 12 for Gocovri (r +0.39, P < 0.001) but not placebo (r +0.12, P = 0.29). The most commonly reported adverse events for Gocovri were hallucination (21%); dizziness, dry mouth, and peripheral edema (16% each); and constipation, falls, and orthostatic hypotension (13% each). CONCLUSION: This post hoc analysis shows potential benefit with Gocovri treatment for the NMS of daytime sleepiness and depression in dyskinetic PD patients. Overall, improvement in NMS scores correlated with improvement in dyskinesia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT02136914 and NCT02274766.
RCT Entities:
INTRODUCTION:Gocovri (amantadine) extended release capsules are approved for treatment of dyskinesia and as a levodopa adjunct for OFF episodes in patients with Parkinson's disease (PD). We report treatment-related effects on non-motor symptoms (NMS) assessed as secondary outcomes in two trials using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I. METHODS:EASE LID and EASE LID 3 enrolled levodopa-treated patients with PD and ≥ 1 h/day ON time with troublesome dyskinesia. Patients were randomized to Gocovri (274 mg) or placebo taken daily at bedtime. Treatment differences from baseline to week 12 in MDS-UPDRS Part I were evaluated for the pooled population (N = 196) from both trials. Correlation analyses of NMS (MDS-UPDRS Part I) with dyskinesia using Unified Dyskinesia Rating Scale (UDysRS) scores were performed. RESULTS: For changes in the MDS-UPDRS Part I items, the treatment difference favored Gocovri in daytime sleepiness (P = 0.006) and depression (P = 0.049) scores, but favored placebo in cognitive impairment (P = 0.038), and hallucinations and psychosis (P < 0.001) scores. The treatment difference for the changes in total Part I score was -0.8, favoring Gocovri (P = 0.22). At baseline, MDS-UPDRS Part I modestly correlated with UDysRS score (r +0.25, P < 0.001), and improvement in NMS correlated with improvement in dyskinesia at week 12 for Gocovri (r +0.39, P < 0.001) but not placebo (r +0.12, P = 0.29). The most commonly reported adverse events for Gocovri were hallucination (21%); dizziness, dry mouth, and peripheral edema (16% each); and constipation, falls, and orthostatic hypotension (13% each). CONCLUSION: This post hoc analysis shows potential benefit with Gocovri treatment for the NMS of daytime sleepiness and depression in dyskinetic PDpatients. Overall, improvement in NMS scores correlated with improvement in dyskinesia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT02136914 and NCT02274766.
Authors: K Ray Chaudhuri; Cristina Prieto-Jurcynska; Yogini Naidu; Tanya Mitra; Belen Frades-Payo; Susanne Tluk; Anne Ruessmann; Per Odin; Graeme Macphee; Fabrizio Stocchi; William Ondo; Kapil Sethi; Anthony H V Schapira; Juan Carlos Martinez Castrillo; Pablo Martinez-Martin Journal: Mov Disord Date: 2010-04-30 Impact factor: 10.338
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow Journal: Mov Disord Date: 2006-07 Impact factor: 10.338
Authors: Nico J Weerkamp; Gerrit Tissingh; Petra J E Poels; Systse U Zuidema; Marten Munneke; Raymond T C M Koopmans; Bastiaan R Bloem Journal: J Am Geriatr Soc Date: 2013-10-01 Impact factor: 5.562
Authors: T A Zesiewicz; K L Sullivan; I Arnulf; K R Chaudhuri; J C Morgan; G S Gronseth; J Miyasaki; D J Iverson; W J Weiner Journal: Neurology Date: 2010-03-16 Impact factor: 9.910
Authors: Paolo Barone; Angelo Antonini; Carlo Colosimo; Roberto Marconi; Letterio Morgante; Tania P Avarello; Eugenio Bottacchi; Antonino Cannas; Gabriella Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Roberto M Gaglio; Rosa M Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E Pontieri; Rocco Quatrale; Silvia Ramat; Rosanna Scala; Giuseppe Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto Journal: Mov Disord Date: 2009-08-15 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Wolfgang Oertel; Karla Eggert; Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Claudia Trenkwalder; Reinhard Ehret; Jean Philippe Azulay; Stuart Isaacson; Larissa Felt; Mary Jean Stempien Journal: Mov Disord Date: 2017-08-21 Impact factor: 10.338
Authors: Robert A Hauser; Rajesh Pahwa; William A Wargin; Cindy J Souza-Prien; Natalie McClure; Reed Johnson; Jack T Nguyen; Rajiv Patni; Gregory T Went Journal: Clin Pharmacokinet Date: 2019-01 Impact factor: 6.447